Results 51 to 60 of about 309 (92)

The Real‐World Analysis of Adverse Events With Two Types of Single‐Inhaler Triple Therapy: A VigiAccess Database Study

Journal of Clinical Pharmacy and Therapeutics, Volume 2025, Issue 1, 2025.
Background The advent of single‐inhaler triple therapies (SITTs), including fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FOR/GLY), has expanded treatment options for chronic obstructive pulmonary disease (COPD).
Baiquan Zhang, Jiayu Bai, Lu Zhou, Hongda Liu   +3 more
wiley   +1 more source

A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases

Frontiers in Pharmacology
Background and objectivesIsocitrate dehydrogenase (IDH) inhibitor drugs (Enasidenib, Ivosidenib) restore normal metabolism and epigenetic regulation in cells, offering a precision-targeted therapeutic option for acute myeloid leukemia (AML) patients with
Mengmeng Peng, Mengmeng Peng, Qian Guo, Zihan Dang, Baiquan Zhang, Manjuan Li, Manjuan Li, Zixuan Wang, Zixuan Wang, Xuemian Lu, Xuemian Lu, Jie Lin   +11 more
doaj   +1 more source

Analysis of publicly available adverse events reported for pediatric patients treated with Janus kinase inhibitors

Pediatric Dermatology, Volume 41, Issue 6, Page 1040-1046, November/December 2024.
Abstract Janus kinase inhibitors (JAKi) are drugs that block tyrosine kinases responsible for transducing cytokine signals. The first JAKi was approved by the US Food and Drug Administration (FDA) in 2011 to treat rheumatoid arthritis in adults. A pediatric indication was not approved until 8 years later, for acute graft‐versus‐host disease. Since then,
Sahithi Talasila, Emily Lee, Eric M. Teichner, Elaine C. Siegfried, Stephanie R. Jackson Cullison   +4 more
wiley   +1 more source

Sintilimab Pharmacovigilance in Real-World Practice: Analysis Utilizing the WHO VigiAccess Database

Abstract Sintilimab, a high-affinity PD-1 inhibitor, blocks the interaction between PD-1 and PD-L1 to restore T-cell function. Clinically used with chemotherapy for cancers like non-small cell lung carcinoma and hepatocellular carcinoma, its adverse event (AE) profile remains critical. Here we conducted the pharmacovigilance analysis of
Youjia Guo, Li Wen, Fangcheng Jiang, Liling Pan, Lei He, Zhaoji Liu, Qiong Wu, Zefeng Lai, Qichun Huang, Yan Li   +9 more
openaire   +1 more source

Multiple Acyl‐Coenzyme A Dehydrogenase Deficiency Is Associated with Sertraline Use – Is There an Acquired Form?

Annals of Neurology, Volume 96, Issue 4, Page 802-811, October 2024.
Objective Multiple acyl‐coenzyme A dehydrogenase deficiency (MADD) is a disorder of fatty acid oxidation and considered an inborn error of metabolism. In recent years, we have diagnosed an increasing number of patients where, despite extensive investigation, no disease‐causing mutations have been found. We therefore investigated a cohort of consecutive
Sofie Sunebo, Hanna Appelqvist, Bo Häggqvist, Olof Danielsson   +3 more
wiley   +1 more source

Cardiovascular toxicity with CTLA‐4 inhibitors in cancer patients: A meta‐analysis

Cancer Innovation, Volume 3, Issue 3, June 2024.
1. CTLA‐4 inhibitors restore the T cell immune response against tumor cells. Tumors and cardiomyocytes, shared some muscle‐specific antigens, which trigger a cross‐reactivity with T cells. The inhibitors make cardiac cells susceptible to injury. 2. CTLA‐4 inhibitors significantly increased the incidence of all‐grade cardiovascular toxicity and severe ...
Huiyi Liu, Lu Fu, Shuyu Jin, Xingdong Ye, Yanlin Chen, Sijia Pu, Yumei Xue   +6 more
wiley   +1 more source

Rising cases of drug‐induced pulmonary fibrosis: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database, 2000–2022

Pharmacoepidemiology and Drug Safety, Volume 33, Issue 5, May 2024.
Abstract Purpose Pulmonary fibrosis (PF) is a severe, progressive disease, which may be caused by exposure to certain medications. Methods We queried the U.S. FDA Adverse Event Reporting System (FAERS) from 2000 to 2022, using the search terms “pulmonary fibrosis” and “idiopathic pulmonary fibrosis” and excluded reports with patients under the age of ...
Kenneth L. McCall, Kelsey R. Hennig, Zachary T. Abe, Danielle N. Dattler, Karyssa L. Hurd, Sophie L. Portnoy, Zoey J. Zagoria   +6 more
wiley   +1 more source

Thyroid and renal tumors in patients treated with long-term lithium: case series from a lithium clinic, review of the literature and international pharmacovigilance reports

International Journal of Bipolar Disorders, 2018
Background Cancer had never been considered as a relevant problem in patients treated with lithium until 2015, when a document published by the European Medicine Agency concluded that long-term use of lithium might induce renal tumors. A few months later,
Luca Ambrosiani, Claudia Pisanu, Arianna Deidda, Caterina Chillotti, Maria Erminia Stochino, Alberto Bocchetta   +5 more
doaj   +1 more source

Comparative Cardiotoxicity Profiles Across Antineoplastic Therapeutic Classes: A Global Analysis Using WHO VigiAccess

Background/Objectives: Antineoplastic therapies have improved cancer survival but remain a major source of treatment-related cardiotoxicity. Comparative global pharmacovigilance evidence across anthracyclines, anti-HER2, and anti-VEGF therapies remains limited. Methods: A retrospective disproportionality study was conducted using Individual Case Safety
Esteban Zavaleta-Monestel, Sebastián Arguedas-Chacón, Jeaustin Mora-Jiménez, Jorge Arturo Villalobos-Madriz, Kevin Tencio-Morales, Brandon Enríquez-Gutiérrez   +5 more
openaire   +1 more source

Analysis of adverse reaction characteristics of four biologics for the treatment of chronic sinusitis with nasal polyps: A descriptive analysis from WHO-VigiAccess

American Journal of Otolaryngology
Chronic rhinosinusitis with nasal polyps (CRSwNP) imposes a significant global disease burden. However, systematic comparisons of adverse drug reaction (ADR) profiles among these agents remain scarce, necessitating large-scale pharmacovigilance evaluation.Utilizing the WHO VigiAccess database, we analyzed 402,778 ADR reports for four biologics ...
Xiaobi, Fang, Tingfeng, Zhou, Fan, Ye
openaire   +2 more sources